Category: Press Release - Page 86 - Psychedelic Alpha

Read more about the article Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide

Post published:December 2, 2021
Post category:Press Release

Read more about the article Psychiatrist and Addiction Researcher, Dr. Henry Kranzler Joins Entheon Advisory Board

Psychiatrist and Addiction Researcher, Dr. Henry Kranzler Joins Entheon Advisory Board

Post published:December 1, 2021
Post category:Press Release

Read more about the article Psyched Wellness Presents AME-1 to Health Canada in Pre-Submission Meeting

Psyched Wellness Presents AME-1 to Health Canada in Pre-Submission Meeting

Post published:December 1, 2021
Post category:Press Release

Read more about the article COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

Post published:December 1, 2021
Post category:Press Release

Read more about the article Awakn Life Sciences Strengthens Executive Leadership Team

Awakn Life Sciences Strengthens Executive Leadership Team

Post published:November 30, 2021
Post category:Press Release

Read more about the article PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio

PharmaTher Granted New Japanese Patent for KETABET™ (Ketamine Combination Formulation), Strengthening Global Patent Portfolio

Post published:November 30, 2021
Post category:Press Release

Read more about the article Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress

Post published:November 30, 2021
Post category:Press Release

Read more about the article MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin

MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin

Post published:November 30, 2021
Post category:Press Release

Read more about the article Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases

Post published:November 30, 2021
Post category:Press Release

Read more about the article MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

Post published:November 30, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.